Benzinga Korea 한국
Benzinga Korea 한국

John Newman's Stock Ratings

Canaccord Genuity Analyst

John Newman is an analyst at Canaccord Genuity. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 07/07/2024

Overall Average Return

-8.76%

Smart Score

46.2%

Overall Average Return Percentile

22nd

Number of Ratings

33
Buy NowGet Alert
07/03/2024RNACBuy Now
Cartesian Therapeutics
$16.60159.04%$38 → $43MaintainsBuyGet Alert
06/27/2024REGNBuy Now
Regeneron Pharmaceuticals
$1.05K9.48%$1152 → $1152MaintainsBuyGet Alert
06/07/2024MCRBBuy Now
Seres Therapeutics
$0.95952.63%$15 → $10MaintainsBuyGet Alert
06/04/2024MRUSBuy Now
Merus
$55.7120.27%$54 → $67MaintainsBuyGet Alert
05/16/2024APTOBuy Now
Aptose Biosciences
$0.79655.95%$15 → $6MaintainsBuyGet Alert
05/13/2024OCUPBuy Now
Ocuphire Pharma
$1.561053.85%$22 → $18MaintainsBuyGet Alert
05/09/2024TSVTBuy Now
2seventy bio
$3.80189.47%$12 → $11MaintainsBuyGet Alert
03/20/2024ACETBuy Now
Adicet Bio
$1.201483.33% → $19ReiteratesBuy → BuyGet Alert
02/29/2024ACLXBuy Now
Arcellx
$55.7752.41%$66 → $85MaintainsBuyGet Alert
01/05/2024ACETBuy Now
Adicet Bio
$1.201483.33%$21 → $19MaintainsBuyGet Alert
11/16/2023ACLXBuy Now
Arcellx
$55.7718.34%$49 → $66MaintainsBuyGet Alert
11/09/2023ACETBuy Now
Adicet Bio
$1.201650%$28 → $21MaintainsBuyGet Alert
08/21/2023REGNBuy Now
Regeneron Pharmaceuticals
$1.05K-5.73%$720 → $992UpgradeHold → BuyGet Alert
08/18/2023REGNBuy Now
Regeneron Pharmaceuticals
$1.05K-31.58%$720 → $720MaintainsHoldGet Alert
08/01/2023IMGNBuy Now
Immunogen
——$23 → $25MaintainsBuyGet Alert
06/28/2023REGNBuy Now
Regeneron Pharmaceuticals
$1.05K-31.58%$953 → $720DowngradeBuy → HoldGet Alert
06/23/2023ONCYBuy Now
Oncolytics Biotech
$1.04380.77% → $5ReiteratesBuy → BuyGet Alert
06/21/2023ACLXBuy Now
Arcellx
$55.77-12.14% → $49ReiteratesBuy → BuyGet Alert
06/16/2023ALLOBuy Now
Allogene Therapeutics
$2.241462.5% → $35ReiteratesBuy → BuyGet Alert
06/12/2023IMGNBuy Now
Immunogen
—— → $19ReiteratesBuy → BuyGet Alert
06/05/2023IMGNBuy Now
Immunogen
——$15 → $19MaintainsBuyGet Alert
05/09/2023ATRABuy Now
Atara Biotherapeutics
$7.50166.66%$1250 → $500MaintainsBuyGet Alert
04/26/2023ACLXBuy Now
Arcellx
$55.77-12.14%$40 → $49MaintainsBuyGet Alert
04/19/2023ACLXBuy Now
Arcellx
$55.77-28.28%$34 → $40MaintainsBuyGet Alert
03/21/2023MCRBBuy Now
Seres Therapeutics
$0.951478.95%$11 → $15MaintainsBuyGet Alert
03/08/2023MCRBBuy Now
Seres Therapeutics
$0.951057.89%$17 → $11MaintainsBuyGet Alert
03/06/2023ONCYBuy Now
Oncolytics Biotech
$1.04380.77%$6 → $5MaintainsBuyGet Alert
01/31/2023SELBBuy Now
Selecta Biosciences
——$10 → $9MaintainsBuyGet Alert
11/16/2022IMGNBuy Now
Immunogen
——$12 → $15MaintainsBuyGet Alert
09/16/2022REGNBuy Now
Regeneron Pharmaceuticals
$1.05K-28.72%$700 → $750MaintainsBuyGet Alert
08/08/2022GBTBuy Now
Global Blood Therapeutics
——$40 → $72UpgradeHold → BuyGet Alert
07/20/2022ACLXBuy Now
Arcellx
$55.77-42.62% → $32Initiates → BuyGet Alert
02/16/2022AGIOBuy Now
Agios Pharmaceuticals
$41.196.82%$52 → $44MaintainsBuyGet Alert

Recent Analyst Stock Rating News

Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Analyst Expectations For Arcellx's Future
Analyst Finds It Difficult To Make Numeric Assumptions For Chemours: Here's Why
BMO analyst downgrades Chemours to Underperform, citing delayed filings, management changes, and difficulty in making earnings assumptions.
FTC And States Take On Amazon In Antitrust Battle: What's Going On? (UPDATE)
Editor's note: This story has been updated to reflect the nature of the lawsuit against Amazon and its intent. 
Why Regeneron Stock Is Trading Lower Today
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares continue to fall Wednesday after news Tuesday that the FDA issued a Complete Response Letter (CRL) for aflibercept 8 mg Biologics License application due to an ongoing review of inspection findings at a third-party filler.
Amazon.com To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Wednesday
Deutsche Bank cut the price target for Walgreens Boots Alliance, Inc. (NASDAQ: WBA) from $46 to $34. Deutsche Bank analyst George Hill downgraded the stock from Buy to Hold. Walgreens shares fell 0.2% to $28.59 in pre-market trading.
Microsoft Files Rebuttal To FTC's Lawsuit Against Activision Deal
Microsoft Corp (NASDAQ: MSFT) has rebutted a Federal Trade Commission lawsuit to block its acquisition of Activision Blizzard Inc (NASDAQ: ATVI) for $75 billion.
Dollar General To $280? Here Are 5 Other Price Target Changes For Monday
Telsey Advisory Group raised the price target on Dollar General Corporation (NYSE: DG) from $260 to $280. However, Telsey Advisory Group analyst Joseph Feldman maintained the stock with an Outperform. Dollar General shares rose 0.1% to $253.96 in pre-market trading.
5 Things You Might Not Know About Formula One Driver Lewis Hamilton
The Abu Dhabi Grand Prix is underway, it's the 22nd and final race in the 2021 Formula 1 season. For the first time since 1974, the Formula 1 finale will decide the winner of the season. Mercedes driver 
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates
The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdicts.
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free
Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2024 Benzinga | All Rights Reserved